LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> WuXi companies consider sale of units impacted by Biosecure;
J&J, Bayer trim staff; Ron Renaud’s latest biotech; and
more : Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Look out next week for our annual Women in Biopharma R&D report celebrating 20 exceptional researchers, entrepreneurs, data experts and more. We’ll kick off a related event on Tuesday at 11 am ET with a fireside chat with Marsha Henderson, the FDA’s former associate commissioner for women’s health, followed by a panel with two of this year’s honorees. You can register here.
WuXi companies consider selling units impacted by Biosecure — report
WuXi AppTec and WuXi Biologics are looking to sell part of their operations that have struggled because of the Biosecure Act, the Financial Times reported. WuXi AppTec said in a statement that it’s “assessing options for continuing WuXi Advanced Therapies’ operations in line with our priorities.” Endpoints News’ Jared Whitlock has the latest.
Eli Lilly resolves tirzepatide shortage
In other manufacturing news, the FDA confirmed on Wednesday that the shortage for Eli Lilly’s blockbuster weight loss and diabetes drug tirzepatide is resolved and Lilly can officially meet present demand. That may create confusion for patients relying on cheaper compounded versions, which are permitted in certain circumstances when a drug is in short supply.
J&J, Bayer trim New Jersey staff
Both Johnson & Johnson and Bayer revealed plans to lay off workers in New Jersey this week, with the moves expected to come before the end of December. J&J will lay off 231 employees while Bayer will lay off 57. Neither elaborated on which units would be affected, but Bayer’s comes amidst a broader, conglomerate-wide reorganization.
Ron Renaud’s latest biotech
Obesity biotechs continue to attract significant financing rounds, and longtime entrepreneur Ron Renaud is behind the latest company, Kailera Therapeutics. The company pulled in $400 million and partnered with Jiangsu Hengrui Pharmaceuticals on four programs. CEO Renaud expects a global Phase 3 to start “as quickly” as it can.
Roche bets on Regor drugs
In what analysts described as a “sensible bolt-on,” Roche spent $850 million in upfront cash to acquire two experimental CDK inhibitors from Regor Pharmaceuticals. The drugs are designed to treat breast and brain cancer, respectively. Roche will take over development after both programs advance through Phase 1 studies.
Prime cuts pipeline, partners with BMS
Gene editing companies have faced cutbacks this year, and now David Liu’s Prime Medicine is joining the fray. The startup,… #lucidquest #genetherapy #celltherapy
Help healthcare entrepreneurs gain visibility, credibility & capital to accelerate your mission, profitability & scalability | Business Power Broker | Advisory Board | Human Capital Amplifier | Podcaster | Author
3moThank you for sharing, Chia Chia Sun! It's inspiring to see Fab Biopharma's commitment to addressing unmet needs in women's health. Fab Biopharma, how do you foresee the advancements in biologics impacting the treatment of autoimmune diseases like Sjögren's syndrome and lupus?